Development of Measles Virus-based Shielded Oncolytic Vectors: Suitability of Other Paramyxovirus Glycoproteins

Overview

Journal Cancer Gene Ther

Specialties Genetics
Oncology
Pharmacology

Date 2013 Jan 12

PMID 23306608

Citations 12

Authors

A W Hudacek

C K Navaratnarajah

R Cattaneo

Affiliations

Soon will be listed here.

Abstract

Antibody-mediated neutralization may interfere with the efficacy of measles virus (MV) oncolysis. To circumvent vector neutralization, we sought to exchange the envelope glycoproteins, hemagglutinin (H) and fusion (F), with those from the non-crossreactive Tupaia paramyxovirus (TPMV). To sustain efficient particle assembly, we generated hybrid glycoproteins with the MV cytoplasmic tails and the TPMV ectodomains. Hybrid F proteins that partially retained fusion function, and hybrid H proteins that retained fusion support activity, were generated. However, when used in combination, the hybrid proteins did not support membrane fusion. An alternative strategy was developed based on a hybrid F protein and a truncated H protein that supported cell-cell fusion. A hybrid virus expressing these two proteins was rescued, and was able to spread by cell fusion; however, it was only capable of producing minimal amounts of particles. Lack of specific interactions between the matrix and the H protein, in combination with suboptimal F-protein processing and inefficient glycoprotein transport in the rescue cells, accounted for inefficient particle production. Ultimately, this interferes with applications for oncolytic virotherapy. Alternative strategies for the generation of shielded MV are discussed.

Citing Articles

Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy.

Wang X, Shen Y, Wan X, Hu X, Cai W, Wu Z J Transl Med. 2023; 21(1):500.

PMID: 37491263 PMC: 10369732. DOI: 10.1186/s12967-023-04360-8.

Preclinical safety assessment of MV-s-NAP, a novel oncolytic measles virus strain armed with an immunostimulatory bacterial transgene.

Viker K, Steele M, Iankov I, Concilio S, Ammayappan A, Bolon B Mol Ther Methods Clin Dev. 2022; 26:532-546.

PMID: 36092362 PMC: 9437807. DOI: 10.1016/j.omtm.2022.07.014.

Strategies to Develop Potent Oncolytic Viruses and Enhance Their Therapeutic Efficacy.

Moaven O, Mangieri C, Stauffer J, Anastasiadis P, Borad M JCO Precis Oncol. 2021; 5.

PMID: 34250395 PMC: 8232397. DOI: 10.1200/PO.21.00003.

targeting of lentiviral vectors pseudotyped with the Tupaia paramyxovirus H glycoprotein bearing a cell-specific ligand.

Argaw T, Marino M, Timmons A, Eldridge L, Takeda K, Li P Mol Ther Methods Clin Dev. 2021; 21:670-680.

PMID: 34141822 PMC: 8166926. DOI: 10.1016/j.omtm.2021.04.012.

MeV-Stealth: A CD46-specific oncolytic measles virus resistant to neutralization by measles-immune human serum.

Munoz-Alia M, Nace R, Tischer A, Zhang L, Bah E, Auton M PLoS Pathog. 2021; 17(2):e1009283.

PMID: 33534834 PMC: 7886131. DOI: 10.1371/journal.ppat.1009283.

References

Navaratnarajah C, Vongpunsawad S, Oezguen N, Stehle T, Braun W, Hashiguchi T . Dynamic interaction of the measles virus hemagglutinin with its receptor signaling lymphocytic activation molecule (SLAM, CD150). J Biol Chem. 2008; 283(17):11763-71. PMC: 2431048. DOI: 10.1074/jbc.M800896200. View

Rose J, Bergmann J . Altered cytoplasmic domains affect intracellular transport of the vesicular stomatitis virus glycoprotein. Cell. 1983; 34(2):513-24. DOI: 10.1016/0092-8674(83)90384-7. View

Galanis E, Hartmann L, Cliby W, Long H, Peethambaram P, Barrette B . Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res. 2010; 70(3):875-82. PMC: 2890216. DOI: 10.1158/0008-5472.CAN-09-2762. View

Msaouel P, Dispenzieri A, Galanis E . Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. Curr Opin Mol Ther. 2009; 11(1):43-53. PMC: 2717625. View

Douglas J, Miller C, Kim M, Dmitriev I, Mikheeva G, Krasnykh V . A system for the propagation of adenoviral vectors with genetically modified receptor specificities. Nat Biotechnol. 1999; 17(5):470-5. DOI: 10.1038/8647. View

Darai G, Matz B, Flugel R, Grafe A, Gelderblom H, Delius H . An adenovirus from Tupaia (tree shrew): growth of the virus, characterization of viral DNA, and transforming ability. Virology. 1980; 104(1):122-38. DOI: 10.1016/0042-6822(80)90371-2. View

Chua K, Wang L, Lam S, Crameri G, Yu M, Wise T . Tioman virus, a novel paramyxovirus isolated from fruit bats in Malaysia. Virology. 2001; 283(2):215-29. DOI: 10.1006/viro.2000.0882. View

Drexler J, Corman V, Muller M, Maganga G, Vallo P, Binger T . Bats host major mammalian paramyxoviruses. Nat Commun. 2012; 3:796. PMC: 3343228. DOI: 10.1038/ncomms1796. View

Cathomen T, Naim H, Cattaneo R . Measles viruses with altered envelope protein cytoplasmic tails gain cell fusion competence. J Virol. 1998; 72(2):1224-34. PMC: 124600. DOI: 10.1128/JVI.72.2.1224-1234.1998. View

10.

Devaux P, von Messling V, Songsungthong W, Springfeld C, Cattaneo R . Tyrosine 110 in the measles virus phosphoprotein is required to block STAT1 phosphorylation. Virology. 2006; 360(1):72-83. DOI: 10.1016/j.virol.2006.09.049. View

11.

Grandi P, Wang S, Schuback D, Krasnykh V, Spear M, Curiel D . HSV-1 virions engineered for specific binding to cell surface receptors. Mol Ther. 2004; 9(3):419-27. DOI: 10.1016/j.ymthe.2003.12.010. View

12.

Garber K . China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst. 2006; 98(5):298-300. DOI: 10.1093/jnci/djj111. View

13.

Stope M, Karger A, Schmidt U, Buchholz U . Chimeric bovine respiratory syncytial virus with attachment and fusion glycoproteins replaced by bovine parainfluenza virus type 3 hemagglutinin-neuraminidase and fusion proteins. J Virol. 2001; 75(19):9367-77. PMC: 114505. DOI: 10.1128/JVI.75.19.9367-9377.2001. View

14.

Vongpunsawad S, Oezgun N, Braun W, Cattaneo R . Selectively receptor-blind measles viruses: Identification of residues necessary for SLAM- or CD46-induced fusion and their localization on a new hemagglutinin structural model. J Virol. 2003; 78(1):302-13. PMC: 303414. DOI: 10.1128/jvi.78.1.302-313.2004. View

15.

Miest T, Yaiw K, Frenzke M, Lampe J, Hudacek A, Springfeld C . Envelope-chimeric entry-targeted measles virus escapes neutralization and achieves oncolysis. Mol Ther. 2011; 19(10):1813-20. PMC: 3188758. DOI: 10.1038/mt.2011.92. View

16.

Radecke F, Spielhofer P, Schneider H, Kaelin K, Huber M, Dotsch C . Rescue of measles viruses from cloned DNA. EMBO J. 1995; 14(23):5773-84. PMC: 394696. DOI: 10.1002/j.1460-2075.1995.tb00266.x. View

17.

Bagai S, Lamb R . Truncation of the COOH-terminal region of the paramyxovirus SV5 fusion protein leads to hemifusion but not complete fusion. J Cell Biol. 1996; 135(1):73-84. PMC: 2121019. DOI: 10.1083/jcb.135.1.73. View

18.

Cattaneo R, Miest T, Shashkova E, Barry M . Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol. 2008; 6(7):529-40. PMC: 3947522. DOI: 10.1038/nrmicro1927. View

19.

Cathomen T, Buchholz C, Spielhofer P, Cattaneo R . Preferential initiation at the second AUG of the measles virus F mRNA: a role for the long untranslated region. Virology. 1995; 214(2):628-32. DOI: 10.1006/viro.1995.0075. View

20.

Tao T, Durbin A, Whitehead S, Davoodi F, Collins P, Murphy B . Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1. J Virol. 1998; 72(4):2955-61. PMC: 109741. DOI: 10.1128/JVI.72.4.2955-2961.1998. View